Amitriptyline/ketamine - Immune Pharmaceuticals

Drug Profile

Amitriptyline/ketamine - Immune Pharmaceuticals

Alternative Names: AmiKet; Amiket™ Nano; EpiCept™ NP-1; Ketamine/amitriptyline; NP-1

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc; National Cancer Institute (USA)
  • Class Cyclohexanes; Dibenzocycloheptenes; Non-opioid analgesics; Small molecules; Tricyclic antidepressants
  • Mechanism of Action Adrenergic uptake inhibitors; Alpha 1 adrenergic receptor antagonists; NMDA receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 16 Sep 2016 Immune Pharmaceuticals enters into a Binding agreement with Novel Pain Therapeutics to fund Maxim Pharmaceuticals
  • 18 Jul 2016 Immune Pharmaceuticals amends its option agreement with Novel Pain Therapeutics for Peripheral neuropathic pain
  • 16 May 2016 Immune Pharmaceuticals and Novel Pain Therapeutics enter into an exclusive 60-day option, to execute a worldwide licence agreement for amitriptyline/ketamine for peripheral neuropathic pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top